Alnylam Pharma Shares Rise 2.44% Despite 183rd Market Rank TTR Revenue Surges 77% to $544M

On August 1, Alnylam Pharmaceuticals (ALNY) rose 2.44% despite a 46.01% decline in trading volume to $710 million, ranking 183rd in market activity. The biotech firm reported Q2 2025 total net product revenues of $672 million, a 64% year-over-year increase driven by 77% growth in TTR franchise revenues to $544 million from AMVUTTRA (vutrisiran). The drug now treats approximately 1,400 ATTR-CM patients and secured approvals in the EU, UK, Japan, and Brazil. Alnylam also initiated the TRITON-CM Phase 3 trial for nucresiran in ATTR-CM and raised 2025 guidance for TTR franchise revenues to $2.175–2.275 billion, reflecting confidence in its RNAi therapeutics pipeline.

Financial results showed a 17% year-over-year revenue increase to $773.7 million, with AMVUTTRA contributing $492 million and ONPATTRO $53 million. Non-GAAP net income per share fell to $0.32, down 43% from 2024. Strategic advancements included Fast Track Designation for nucresiran in ATTR-CM and Phase 1 trials for mivelsiran in Alzheimer’s disease. Alnylam plans to present KARDIA-3 trial data for zilebesiran in hypertension at the ESC Congress in August and initiate a cardiovascular outcomes trial with Roche in H2 2025.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day delivered a 166.71% return from 2022 to the present, outperforming the benchmark return of 29.18% by 137.53%. This highlights the role of liquidity concentration in driving short-term stock prices, particularly in volatile markets.